Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response

EGFR activation is both a key molecular driver of disease progression and the target of a broad class of molecular agents designed to treat advanced cancer. Nevertheless, resistance develops through several mechanisms, including activation of AKT signaling. Though much is known about the specific mo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sangodkar, Jaya, Dhawan, Neil S., Melville, Heather, Singh, Varan J., Yuan, Eric, Rana, Huma, Izadmehr, Sudeh, Farrington, Caroline, Mazhar, Sahar, Katz, Suzanna, Albano, Tara, Arnovitz, Pearlann, Okrent, Rachel, Ohlmeyer, Michael, Galsky, Matthew, Burstein, David, Zhang, David, Politi, Katerina, DiFeo, Analisa, Narla, Goutham
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2012
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3386822/
https://ncbi.nlm.nih.gov/pubmed/22653055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI62058
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires